fb-pixel Skip to main content

Impossible Foods sues Ginkgo spinout Motif in ‘beef replica’ dispute

It claims Boston-based Motif FoodWorks copied a patented process for making alternative ‘meat’ products. Motif calls the complaint ‘baseless.’

Intellia Therapeutics sinks as patent ruling overshadows Crispr promise

The Cambridge-based biotechnology company fell by the most in more than five years the US Patent and Trademark Office invalidated a key patent Intellia licensed.

Intellia leases space for 140,000-square-foot manufacturing facility in former Waltham BSC

Biotech companies have long considered Massachusetts a global hub for drug research, and increasingly, they are choosing to make their products here, too.

CEO Gerngross resigns from Waltham biotech working on COVID-19 antibody treatment

Adagio Therapeutics had touted its potential to play a meaningful role in the fight against the pandemic, but fell out of favor in recent months.

Agios wins FDA approval for pill to treat rare blood disease
The Cambridge company’s CEO says the medicine for people with pyruvate kinase deficiency has the potential to become a blockbuster drug.

An overlooked weapon to fight Omicron: T cells
Several new studies suggest that vaccinated people have strong T cell immunity against the variant, even when antibodies wane.

Latest Headlines in Biotech

People who worked with Eric Lander at the Broad Institute of MIT and Harvard describe him as hard-driving and particular.

Lander was a tough boss at the Broad Institute, but not sexist, say former colleagues

Their reflections of Eric Lander paint a picture of a brilliant and complicated scientist who could be difficult.

A "Sanofi Genzyme" sign in the lobby at 50 Binney Street.

Eleven years after buying Genzyme, Sanofi officially ditches subsidiary’s storied name

The move jettisons the name of a storied Massachusetts biotechnology company that helped transform the drug industry in the 1980s and anchored the life sciences cluster.

Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.

Biogen’s 2022 outlook leaves investors wanting, shares slip

Its Alzheimer’s treatment brought in only $3 million last year following its debut. But the company, based in Cambridge, Massachusetts, also reported eroding sales from other key products.

Boston-based Gelesis makes an orally administered aid for weight management called Plenity.

Gelesis slashes marketing team after disappointing debut

The Boston biotech let 140 contractors go in mid-January after it didn't raise as much money from its SPAC deal as planned.

Marc Archambault, a 70-year-old resident of South Kingstown, RI, spoke with staff members at Butler Hospital as he received his first intravenous infusion of Aduhelm in June 2021.

Medicare limits coverage of $28,000-a-year Alzheimer’s drug from Biogen

Its benefits have been widely questioned, sparking a tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.

Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites.

Medicare is poised to make pivotal announcement on Biogen’s Alzheimer’s drug

Federal officials this week are expected to make a long-awaited announcement that could help decide the fate of Aduhelm, Biogen’s new Alzheimer’s drug, which costs over $28,000 annually and has stirred more controversy than any medication in years.

Moderna chief executive Stéphane Bancel.

Moderna says Omicron-specific vaccine won’t be ready before fall; data in young children imminent

Speaking at the virtual J.P. Morgan Healthcare Conference, Moderna chief executive Stéphane Bancel also said the company is working on an all-in-one annual vaccine for respiratory illnesses.

Beam Therapeutics chief executive John Evans (left), and president and chief scientific officer Giuseppe Ciaramella.

Beam Therapeutics inks $300 million gene-editing collaboration with Pfizer

The companies announced Monday that they are partnering to work on new medicines for diseases involving the liver, muscles, and central nervous system.